ipragliflozin + nateglinide

**ipragliflozin + nateglinide** is a fixed-dose combination of two oral antidiabetic agents, designed for the treatment of type 2 diabetes mellitus. Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, which reduces blood glucose by promoting urinary glucose excretion in an insulin-independent manner. Nateglinide is a short-acting, beta-cell-selective KATP channel blocker (meglitinide class), which stimulates rapid, glucose-dependent insulin secretion by closing ATP-sensitive potassium channels on pancreatic beta cells, leading to membrane depolarization, calcium influx, and insulin release. This combination targets both fasting and postprandial hyperglycemia: ipragliflozin primarily lowers fasting plasma glucose through renal glucose loss, while nateglinide bluntly and rapidly addresses postprandial glucose spikes by restoring early-phase insulin secretion[1][2][3][4][5][6].